Witnessing a Historic Moment in U.S.-Japan Relations

Masao Yoshida is the President and CEO of Astellas US LLC.Prime Minister Shinzo Abe addressed a Joint Session of Congress on Wednesday, April 29, 2015 at the U.S. Capitol. It was a historic...
Read More
ICYMI: A Broad Coalition of Stakeholders Continue to Raise Concerns about Patent Litigation Reform

As we’ve shared here, here and here on the Catalyst, Congress is currently considering new patent litigation reform legislation. The Innovation Act (H.R. 9) will soon be marked up in the U.S. House...
Read More
World IP Day: The Foundation of Modern Life in America

This week marks the celebration of World Intellectual Property Day – an opportunity to reflect on and highlight the many ways that patents and trademarks serve as the very foundation of modern life...
Read More
Ask About Adherence: Q&A with PhRMA Foundation Young Investigator Adherence Grantee - Sujit S. Sansgiry

Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Sujit S. Sansgiry, PhD, a 2015 PhRMA Foundation Young Investigator Adherence...
Read More
What They Are Saying: Close Patent Loopholes That Threaten Innovation for Patients

“When we developed these proceedings, we never thought people would use them this way” - Former general counsel of the PTO New administrative proceedings at the Patent and Trademark Office (PTO)...
Read More
Prime Minister Abe’s Visit is an Important Step Toward Strengthening Innovation

Today was an historic day for Japanese Prime Minister Shinzo Abe, who arrived in the U.S. on Sunday for a week-long visit and became the first Japanese leader to address a joint session of Congress....
Read More
ICYMI: 340B Program Raises Eyebrows in North Carolina

In case you missed it, a recent article in The Charlotte Observer spotlights new revelations about the 340B drug discount program in North Carolina. An inquiry by Senator Chuck Grassley (R-Iowa) in...
Read More
Three Things You Need to Know about Today's WSJ Story on Medicine Prices

In case you missed it, a Wall Street Journal article this morning explored pricing trends in the biopharmaceutical industry. In the piece, the authors correctly stated that spending on retail...
Read More
Patients: They're at the Table – It’s About Time to Ask Them What Should be Served

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Monday: What You Need To Know About Part D Appeals

Did you know there is a process in Medicare Part D to appeal a coverage decision made by your plan about a medicine you need? Meaning, if a beneficiary is told at the pharmacy counter that his or her...
Read More
Why Cross-Country Comparisons on Drug Prices are Misleading

Too often, critics greatly exaggerate price differences between the U.S. and other countries to create an erroneous impression that medicines are a major driver of U.S. health care cost growth –...
Read More
Patient Profile: Out-of-Pocket Cost Burden for Patients Treating Mental Health Conditions

We’ve been exploring profiles of patients managing different chronic conditions like cancer and rheumatoid arthritis and the burdensome out-of-pocket costs they face. Unfortunately, for many like...
Read More
What They Are Saying: Stakeholders Raise Concerns about Patent Litigation Reform

Patents are critical to the innovation ecosystem, and the lifeblood of the biopharmaceutical industry. Protecting and enforcing them is essential to keeping the engine of scientific discovery running...
Read More
Ask About Adherence: PhRMA Foundation Young Investigator Adherence Grant Program

Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. But, this week we are straying from our regular format to announce that the PhRMA Foundation has awarded...
Read More
ICYMI – Cancer Leaders Lay Out Policy Road Map for Continued Progress

In case you missed it, a special report, “Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care,” published online yesterday in the American Association for Cancer Research (AACR)...
Read More
Earth Day 2015: Green Initiatives are Good for Business and the Environment

Earth Day provides us all with an opportunity to consider the role each of us can play in protecting the Earth’s natural resources. The nation’s innovative biopharmaceutical companies spend...
Read More
What You Need to Know about the New Kaiser Poll

Spending on retail prescription medicines has consistently accounted for just 10 percent of health care spending, even though biopharmaceutical companies have brought more than 500 medicines to U.S....
Read More
PhRMA Member Companies Invested $51.2 Billion in R&D in 2014

Earlier today, the Pharmaceutical Research and Manufacturers of America (PhRMA) announced that its member companies have invested more than $600 billion in the search for new treatments and cures...
Read More
Continuing and Expanding the Georgetown-PhRMA Fellowship Program

This is an exciting time for biomedical research as innovation is at an all-time high. To continue this positive trajectory, researchers need training opportunities that embrace team science...
Read More
Medicare Monday: Medication Therapy Management in Part D – Another Potential Opportunity for Savings

Over the past few weeks, we’ve discussed how Medicare Part D helps patients with a number of different conditions including Parkinson’s, artery plaque, congestive heart failure, chronic obstructive...
Read More
Week in Review: The Latest from PhRMA

Spending on Medicines: The Big Picture – PhRMA’s new video explains how high generic utilization rates, competition among brand-name medicines and aggressive tactics by insurers and pharmacy benefit ...
Read More
ICYMI: Has the 340B Program Lost Its Way?

In case you missed it, an article in the latest issue of Managed Care Magazine explores the 340B drug discount program. Columnist Richard Kirkner calls 340B a “well-intended program [that] has become...
Read More
Spending on Medicines: The Big Picture

There has been a lot of discussion lately on spending on prescription medicines. And too often this dialogue fails to acknowledge that retail prescription medicines have consistently accounted for...
Read More
Paying for Personalized Medicine: Protecting the Future of Patient-Centered Cancer Care

At a time of unprecedented scientific breakthroughs in oncology, personalized medicine is enabling more accurate diagnoses and more targeted treatments, increasing the overall efficiency and...
Read More
How a Competitive Biopharmaceutical Marketplace Helps to Control Costs

Too often conversations on the cost of medicines fail to acknowledge the competitive biopharmaceutical market that exists in the U.S., which helps to control costs while encouraging the development...
Read More
Putting 2014 Figures on Prescription Drug Spending in Context

Last year was unique for our nation’s health care system. Nearly 10 million uninsured patients gained health insurance coverage – the largest gain in four decades -- and the FDA’s Center for Drug...
Read More
Medicare Monday: How Part D Helps Parkinson’s Patients

We often talk about the importance of adherence on The Catalyst, but it’s a topic that isn’t widely understood. Consider this: when patients prematurely discontinue their medication, it costs the...
Read More
Week in Review: The Latest from PhRMA
By Mollymae Metheny | April 10, 2015
The reality of prescription drug spending in Medicaid, more than 240 Medicines in Development to treat blood cancers, PPA celebrates its 10th anniversary, look at a patient with rheumatoid arthritis...
Read More
PhRMA & LLS: More than 240 Medicines in Development for Blood Cancers

It’s hard to believe, but – this year alone – more than 162,000 Americans will be diagnosed with a form of blood cancer, such as leukemia, lymphoma or myeloma. Fortunately, science has advanced...
Read More
The Reality of Prescription Drug Spending in Medicaid

Recent rhetoric on spending in state Medicaid programs often overstates the cost impact of prescription medicines and ignores the competitive biopharmaceutical market that exists in the U.S., which...
Read More
Patient Profile: Out-of-Pocket Cost Burden for Rheumatoid Arthritis Patient

Last month, we walked through how managing chronic myeloid leukemia with a health insurance exchange plan can leave patients with burdensome out-of-pocket costs and put patients’ access to medicines...
Read More
Ask About Adherence: Q&A with Pharmacy Quality Alliance

Ask About Adherence is a blog series featuring Q&A’s with experts in medication adherence. In this post, we speak with Laura Cranston, Pharmacy Quality Alliance (PQA) executive director, on...
Read More
Paving the Way for Better Cancer Treatments

Last week, during Ken Burns’ documentary, Cancer: The Emperor of All Maladies, Americans heard about the scientific community’s decades-long, tireless fight to treat and cure cancer, an incredibly...
Read More
Partnership for Prescription Assistance Celebrates 10th Anniversary

This week the Partnership for Prescription Assistance (PPA) celebrates its 10th anniversary of connecting uninsured or underinsured Americans to programs that provide prescription medicines for free...
Read More
Medicare Monday: Medicare Part D Helps Reduce Spending in Parts A and B, Too

Last week, we talked about how Medicare Part D helps seniors live better by facilitating access to needed medicines and helping to avoid the use of more costly medical services. What we didn’t cover...
Read More
Progress to Improve Patient Lives - A Review

Almost three years ago, PhRMA President and CEO John Castellani wrote a Catalyst post highlighting the evolution of the fight against cancer. He concluded that to advance progress, stakeholders from...
Read More
ICYMI – WSJ: The Arrow of U.S. Cancer Progress

In case you missed it, The Wall Street Journal editorial team published an opinion piece yesterday online and in today’s print edition on the progress biopharmaceutical research companies have made...
Read More
Week in Review: The Latest from PhRMA
By Mollymae Metheny | April 3, 2015
Communications with health care professionals, advances in cancer treatment documentary, importance of safe drug disposal and more Communications with Health Care Professionals – Mit Spears, Jeff...
Read More
The Vital Role of Clinical Outcome Assessments in Patient-Centered Drug Development
By Gabriela Lavezzari | April 3, 2015
The Food and Drug Administration (FDA) Public Workshop on Clinical Outcomes Assessment Development and Implementation: Opportunities and Challenges, held earlier this week, was an important...
Read More
340B Paradox: As the Uninsured Rate Drops, 340B Program Continues to Grow

Recent studies show the Affordable Care Act (ACA) has reduced the uninsured rate and lowered the amount of uncompensated care that hospitals provide. Paradoxically, these welcome trends are also...
Read More
3 Reasons Patient Engagement is the Backbone of Scientific Discovery

Each year, the National Health Council (NHC) convenes the Voluntary Health Leadership Conference (VHLC) – a forum that brings together patient advocacy organizations to share information about the...
Read More
Embracing 21st Century Information Sharing: Defining a New Paradigm for the FDA and Communications with Health Care Professionals
By Mit Spears | April 1, 2015
The Food and Drug Administration (FDA) protects public health by approving new medicines for patients, ensuring unsafe treatments are not used and monitoring the evolution of scientific insights...
Read More